Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

Core Insights - BrainsWay Ltd. has introduced new clinical data demonstrating a faster, noninvasive treatment for depression, enhancing its neuromodulation platform aimed at improving brain health [1][2] Group 1: Clinical Efficacy - The SWIFT™ accelerated Deep TMS™ protocol achieved an 87.8% response rate and a 78.0% remission rate for Major Depressive Disorder, comparable to traditional methods [10] - The median time to remission was reduced to 21 days with SWIFT compared to 28 days under the standard protocol [10][8] - Approximately 70% of participants reported no longer suffering from severe quality of life impairment, and around 60% returned to normal functioning after treatment [9] Group 2: Patient Experience - Patients reported earlier symptom improvement and significant enhancements in quality of life, with scores improving by approximately 32 percentage points from baseline by week six [11] - The proportion of patients experiencing severe functional impairment decreased from 85-100% at baseline to 15-17% by the end of treatment [11] Group 3: Accessibility and Impact - The SWIFT approach reduces the number of clinic visits in the acute phase by about 70%, addressing logistical barriers that hinder access to treatment [3][4] - The innovation is expected to improve patient retention and expand clinical options, particularly as demand for non-drug therapies rises [3][4] - BrainsWay's CEO emphasized the importance of addressing accessibility and scalability in mental health innovation, marking a new era for the company [7]